Center-Authored Papers

Filters: Author is Chapuis, Aude G  [Clear All Filters]
2019
Hay KA, Gauthier J, Hirayama AV, Voutsinas JM, Wu Q, Li D, Gooley TA, Cherian S, Chen X, Pender BS et al..  2019.  Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy.. Blood. 133(15):1652-1663. Abstract
2017
Oda SK, Daman AW, Garcia NM, Wagener F, Schmitt TM, Tan X, Chapuis AG, Greenberg PD.  2017.  A CD200R-CD28 fusion protein appropriates an inhibitory signal to enhance T cell function and therapy of murine leukemia.. Blood. 130(22):2410-2419. Abstract
Chapuis AG, Desmarais C, Emerson R, Schmitt TM, Shibuya K, Lai I, Wagener F, Chou J, Roberts IM, Coffey DG et al..  2017.  Tracking the Fate and Origin of Clinically Relevant Adoptively Transferred CD8(+) T Cells In Vivo.. Science immunology. 2(8) Abstract
2016
Chapuis AG, Roberts IM, Thompson JA, Margolin KA, Bhatia S, Lee SM, Sloan HL, Lai IP, Farrar EA, Wagener F et al..  2016.  T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 34(31):3787-3795. Abstract
Chapuis AG, Lee SM, Thompson JA, Roberts IM, Margolin KA, Bhatia S, Sloan HL, Lai I, Wagener F, Shibuya K et al..  2016.  Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient.. The Journal of experimental medicine. 213(7):1133-9. Abstract
Hossain NM, Chapuis AG, Walter RB.  2016.  T-Cell Receptor-Engineered Cells for the Treatment of Hematologic Malignancies.. Current hematologic malignancy reports. Abstract
2015
Schmitt TM, Stromnes IM, Chapuis AG, Greenberg PD.  2015.  New Strategies in Engineering T-cell Receptor Gene-Modified T Cells to More Effectively Target Malignancies.. Clinical cancer research : an official journal of the American Association for Cancer Research. 21(23):5191-5197. Abstract
2014
Chapuis AG, Afanasiev OK, Iyer JG, Paulson KG, Parvathaneni U, Hwang JH, Lai I, Roberts IM, Sloan HL, Bhatia S et al..  2014.  Regression of metastatic Merkel cell carcinoma following transfer of polyomavirus-specific T cells and therapies capable of re-inducing HLA class-I.. Cancer immunology research. 2(1):27-36. Abstract
Stromnes IM, Schmitt TM, Chapuis AG, Hingorani SR, Greenberg PD.  2014.  Re-adapting T cells for cancer therapy: from mouse models to clinical trials.. Immunological reviews. 257(1):145-64. Abstract
2013
Chapuis AG, Ragnarsson GB, Nguyen HN, Chaney CN, Pufnock JS, Schmitt TM, Duerkopp N, Roberts IM, Pogosov GL, Ho WY et al..  2013.  Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients.. Science translational medicine. 5(174):174ra27. Abstract
2012
Chapuis AG, Thompson JA, Margolin KA, Rodmyre R, Lai IP, Dowdy K, Farrar EA, Bhatia S, Sabath DE, Cao J et al..  2012.  Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype.. Proceedings of the National Academy of Sciences of the United States of America. 109(12):4592-7. Abstract
Chapuis AG, Yee C.  2012.  Cancer ImmunotherapyMonitoring Antigen-Specific Responses in Clinical Trials of Cancer Immunotherapy. :425-453.
2011
Chapuis AG, Casper C, Kuntz S, Zhu J, Tjernlund A, Diem K, Turtle CJ, Cigal ML, Velez R, Riddell SR et al..  2011.  HIV-specific CD8+ T cells from HIV+ individuals receiving HAART can be expanded ex vivo to augment systemic and mucosal immunity in vivo.. Blood. 117(20):5391-402. Abstract